Biogen hands Denali $1B-plus in cash, $1B-plus in milestones to partner on late-stage Parkinson’s drug
Biogen is handing over more than a billion dollars cash to partner with the up-and-coming neurosciences crew at Denali on a new therapy for Parkinson’s. And the big biotech is ready to pile on more than a billion dollars more in milestones — if the alliance is a success.
For Biogen $BIIB, the move on Denali’s small molecule inhibitors of LRRK2 puts them in line to collaborate on a late-stage program for DNL151, which is scheduled to start next year.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 98,500+ biopharma pros reading Endpoints daily — and it's free.